Drug intelligence / Profile preview

demethoxy feruloyl acetone

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral, Intramuscular, Intraperitoneal, Subcutaneous, Intravenous, Topical
01

Overview

Demethoxy feruloyl acetone is a natural degradant of curcumin formed during heating, structurally similar to feruloylacetone but lacking a methoxy group on the aromatic ring[1][3]. It has demonstrated **antiproliferative and proapoptotic effects in colon cancer cell models**, specifically inhibiting proliferation and inducing cell cycle arrest (G2/M phase) and apoptosis, with mechanisms involving suppression of the phosphorylated mTOR/STAT3 pathway and activation of p53/p21 and cyclin-B1[1][3][5]. DFER also induces ROS elevation and mitochondrial changes in cancer cells. It has shown antioxidant activity, though markedly less than feruloylacetone[3]. Recently, DFER has been studied for its **potential to mitigate obesity-related glucose intolerance and muscle atrophy**, indicating possible metabolic benefits[5].

Other names
demethoxy feruloylacetoneDFER
02

Targets

STAT3 (Signal Transducer and Activator of Transcription 3)mTOR (Mammalian target of rapamycin kinase)CCNB1 (Cyclin B1)CDKN1A (Cyclin-dependent kinase inhibitor 1A)TP53 (Cellular Tumor Antigen p53 R175H)

Beyond the preview

Go deeper on demethoxy feruloyl acetone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on demethoxy feruloyl acetone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call